BioVie Advances Phase 2 Parkinson's Disease Trial with Bezisterim, Targeting Neuroinflammation and Insulin Resistance
Key Insights
BioVie will host a virtual KOL event on May 7, 2026, featuring Dr. Suzanne de la Monte to discuss bezisterim's mechanism of action in addressing neurodegenerative disease pathology.
The company's SUNRISE-PD Phase 2 trial is evaluating bezisterim as a monotherapy for motor and non-motor symptoms in Parkinson's patients not treated with carbidopa/levodopa, with topline results expected mid-2026.
Bezisterim is an oral small molecule that crosses the blood-brain barrier and selectively inhibits inflammation-driven ERK (search) and NF-κB (search) pathways while reducing insulin resistance without suppressing immune function.
BioVie Inc. (NASDAQ: BIVI) announced plans to host a virtual key opinion leader event on May 7, 2026, ahead of anticipated topline data from its Phase 2 SUNRISE-PD trial evaluating bezisterim for Parkinson's disease (search) treatment. The event will feature Dr. Suzanne de la Monte from Brown University Warren Alpert Medical School (search), who will discuss how bezisterim's mechanism of action could potentially address the pathology and progression of neurodegenerative diseases.
Novel Mechanism Targets Neuroinflammation
Bezisterim (NE3107) represents a novel approach to treating Parkinson's disease (search) by targeting inflammation and insulin resistance, which contribute significantly to disease development and progression. The investigational oral small molecule crosses the blood-brain barrier and has demonstrated potential to reduce insulin resistance while selectively inhibiting inflammation-driven ERK (search) and NF-κB (search)-stimulated inflammatory mediators without inhibiting their homeostatic functions.
According to BioVie CEO Cuong Do, bezisterim functions as a modulator of inflammation, specifically modulating TNF-alpha production. In various clinical trials, patients treated with bezisterim have experienced reduced inflammation and associated insulin resistance. "In our Parkinson's trial, Parkinson's patients have seen improved muscle control," Do stated during a recent company presentation.
Phase 2 Trial Design and Previous Results
The ongoing SUNRISE-PD trial is evaluating whether bezisterim alone can improve motor and non-motor symptoms in Parkinson's patients who have not been treated with carbidopa/levodopa. This represents a significant departure from previous studies that combined bezisterim with existing therapies.
BioVie has already completed a Phase 2 study demonstrating promising efficacy signals. In that trial, patients with moderate to severe stage Parkinson's disease (search) taking bezisterim with levodopa showed better motor control and reported fewer morning symptoms compared to those taking levodopa alone. Importantly, few drug-related side effects were observed during the study.
Broader Therapeutic Pipeline
Beyond Parkinson's disease (search), bezisterim is being investigated across multiple neurological conditions. The company is conducting the ADDRESS-LC trial, enrolling approximately 200 patients to evaluate whether bezisterim may help reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long COVID (search). The hypothesis being studied suggests these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via NF-κB (search) activation.
In Alzheimer's disease (search), BioVie has conducted both Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, with patients experiencing improved cognition and function. Additionally, patients across studies have experienced lower levels of DNA methylation, which represents a modulation of the biological aging process.
Expert Leadership and Scientific Foundation
Dr. Suzanne de la Monte, who will present at the upcoming KOL event, brings extensive expertise in neurodegeneration research. She serves as Professor in Pathology and Laboratory Medicine, Neurology, and Neurosurgery at Brown University's Warren Alpert Medical School and Chief of Pathology & Laboratory Medicine at the Providence VA Medical Center. Dr. de la Monte leads programs in basic, translational, and clinical research on mechanisms and consequences of brain insulin resistance and metabolic dysfunction, having coined the term 'Type 3 Diabetes.' She has authored over 300 peer-reviewed articles.
Timeline and Market Expectations
BioVie expects topline results from the SUNRISE-PD trial in mid-2026, with the May 7 KOL event providing important context ahead of data readout. The company's approach of targeting neuroinflammation and insulin resistance represents a potentially differentiated mechanism in the competitive Parkinson's disease (search) treatment landscape.
The drug candidate's ability to modulate key pathways involved in neuroinflammation, including ERK (search), NF-κB (search), and TNF-α (search), while maintaining a low risk of drug-drug interactions, positions it as a potentially valuable addition to current treatment options for the millions of patients affected by neurodegenerative diseases.